Advocates Demand Expanded Genetic Testing Access to Unlock Motor Neurone Disease Treatments
Advocates and patients are calling for expanded access to comprehensive genetic testing for Motor Neurone Disease (MND) to enable the use of targeted, mutation-specific therapies, according to reports by Newstalk ZB. The push for better diagnostic tools follows the development of precision medicines that only work for patients with specific genetic markers, leaving those without testing unable to access potentially life-extending treatment.
Why is genetic testing now critical for MND patients?
The urgency for increased testing stems from a shift in how Motor Neurone Disease is treated. Traditionally, MND treatments focused on symptom management and slowing general decline. However, the emergence of precision medicine has introduced drugs designed to target the root genetic cause of the disease in specific subsets of patients.
According to medical reports highlighted by Newstalk ZB, certain genetic mutations, such as those in the SOD1 gene, are now targets for specific therapies. For example, the drug Tofersen was developed specifically for patients with the SOD1 mutation. If a patient is not genetically tested, they cannot be prescribed these targeted therapies, regardless of whether they possess the mutation.
Precision medicine requires a “lock and key” approach. The drug is the key, but the genetic test identifies the lock. Without the test, clinicians are unable to determine which patients are eligible for the newest wave of pharmaceutical interventions.
| Treatment Approach | Focus | Requirement | Goal |
|---|---|---|---|
| Standard Care | Symptom Management | Clinical Diagnosis | Improve quality of life; slow general progression |
| Precision Care | Genetic Mutation | Genetic Testing (e.g., SOD1) | Target the specific protein/gene causing neurodegeneration |
The gap between diagnosis and genetic identification
A significant portion of MND cases are classified as “sporadic,” meaning they appear without a clear family history. However, research indicates that a percentage of these sporadic cases actually have an underlying genetic cause. According to patient advocates, current testing protocols often overlook these patients because they lack a family history of the disease.
This creates a diagnostic gap. Patients who would benefit from targeted therapies are missed because the healthcare system often reserves genetic testing for “familial” cases. Advocates argue that the distinction between sporadic and familial MND is an outdated barrier to care. They suggest that every person diagnosed with MND should receive a full genetic screen to ensure no one is denied a targeted treatment based on their family tree.
The lack of standardized, widespread testing means that the identification of eligible patients is currently inconsistent. This inconsistency results in a “postcode lottery” where access to life-altering diagnostics depends on the specific clinic or specialist a patient visits.
How genetic mutations drive Motor Neurone Disease
MND is a group of diseases that affect the motor neurons in the brain and spinal cord. When these neurons die, the brain can no longer initiate and control muscle movement. Genetic testing looks for specific mutations in the DNA that cause these neurons to malfunction or die prematurely.
The role of SOD1 and C9orf72
Two of the most discussed genetic markers in MND research are the SOD1 and C9orf72 genes. According to clinical data, mutations in the SOD1 gene cause the protein to misfold, which becomes toxic to motor neurons. Targeted therapies like Tofersen work by reducing the production of this toxic protein.
The C9orf72 mutation is another common genetic driver, often linked to both MND and Frontotemporal Dementia (FTD). Identifying this mutation is critical not only for current treatment options but for participating in clinical trials that specifically target the C9orf72 pathway.
The difference between familial and sporadic MND
- Familial MND: Cases where a genetic mutation is passed down through generations. These are historically the primary candidates for genetic testing.
- Sporadic MND: Cases that occur without a known family history. These may be caused by a random mutation (de novo) or environmental factors, but they can still harbor targetable genetic markers.
The barriers to implementing widespread genetic testing
Despite the clear benefit of identifying targetable mutations, several systemic hurdles prevent the rollout of universal genetic testing for MND patients. According to health policy analysts, these barriers are primarily financial, logistical, and educational.
Cost and funding
Comprehensive genetic sequencing is expensive. Many public health systems operate on budgets that prioritize the most common treatments over expensive, niche diagnostics. Advocates argue that the cost of testing is a fraction of the long-term care costs for an untreated patient, but the immediate budgetary impact remains a deterrent for health boards.
Infrastructure and specialization
Performing and interpreting genetic tests requires specialized laboratory equipment and genetic counselors. There is a shortage of professionals capable of explaining the implications of a positive genetic test to a patient and their family, especially regarding the risk to children and siblings.
Clinical inertia
Medical practice often lags behind scientific discovery. Some clinicians may still view genetic testing as a research tool rather than a clinical necessity. This inertia means that tests are not always ordered at the point of diagnosis, delaying the window of opportunity for targeted treatment.
“The science has evolved, but the access to that science hasn’t. We have drugs that can target the disease, but we aren’t testing enough people to find out who can actually use them.”
Implications for family members and ethics
Expanding genetic testing for MND introduces complex ethical dilemmas. Because MND can be hereditary, a positive test for one patient automatically provides information about their biological relatives.
The “Right Not to Know”
If a patient is found to have a mutation like C9orf72, their children have a 50% chance of carrying the same mutation. This creates a tension between the duty to warn family members and the individual’s right not to know their future health status, especially for a disease that currently has no absolute cure.
Psychological impact
Genetic testing can lead to significant psychological distress. Finding out that a disease is hereditary can cause guilt in parents or anxiety in offspring. This is why advocates emphasize that increased testing must be paired with increased access to genetic counseling.
Comparing the impact: Targeted vs. General therapy
To understand the push for better testing, it is necessary to contrast the outcomes of general MND care with the potential of precision medicine. While general therapies aim to maintain function, targeted therapies aim to alter the biological trajectory of the disease.
In general therapy, the approach is reactive. Doctors treat the muscle atrophy and respiratory failure as they occur. In precision medicine, the approach is proactive. By identifying the genetic driver, doctors can potentially stop the production of the toxic proteins before the neurons are destroyed.
The effectiveness of these targeted drugs is often dependent on how early they are administered. This makes the timing of genetic testing critical; a test performed three years into the disease may be less useful than one performed at the onset of symptoms.
The global context of MND diagnostics
The calls for better testing in New Zealand and other regions reflect a global trend toward “personalized medicine.” In the United States and parts of Europe, some insurance providers and health systems have begun integrating genetic screening earlier in the diagnostic pathway for neurodegenerative diseases.
However, the disparity in access remains high. Low- and middle-income countries often have virtually no access to the genetic sequencing required to identify SOD1 or C9orf72 mutations, meaning the benefits of new MND drugs are currently limited to wealthy nations with advanced healthcare infrastructure.
International patient advocacy groups are pushing for a global standard of care that includes genetic testing as a baseline requirement for any MND diagnosis. This would ensure that clinical trial data is more accurate and that patient recruitment for new drugs is based on genetic reality rather than clinical guesswork.
Key points regarding the current state of MND testing
- Targeted Drugs: New medications only work for patients with specific genetic mutations.
- Testing Gap: Many “sporadic” MND patients have genetic mutations that go undetected due to a lack of testing.
- Urgency: Early detection of mutations is essential for the maximum efficacy of precision therapies.
- Barriers: High costs and a lack of genetic counselors hinder the rollout of universal screening.
- Ethics: Genetic results impact family members, necessitating robust counseling services.
Frequently Asked Questions
What is the main reason for the calls for better genetic testing in MND?
The primary reason is the development of precision medicines. Some new drugs only work for patients with specific genetic mutations (such as SOD1). Without genetic testing, doctors cannot identify which patients are eligible for these targeted treatments, effectively denying them access to potentially life-saving medication.
Can someone with sporadic MND still have a genetic mutation?
Yes. While “sporadic” means there is no known family history, a person can still have a genetic mutation that caused the disease. This could be a new mutation (de novo) or a mutation that was not expressed in previous generations. Testing is the only way to confirm this.
Does a genetic test provide a cure for Motor Neurone Disease?
A genetic test itself is a diagnostic tool, not a cure. However, it is the prerequisite for accessing targeted therapies that aim to slow the progression of the disease by addressing the specific genetic cause.
Who should be tested for MND genetic markers?
Advocates argue that all patients diagnosed with MND should be offered genetic testing, regardless of whether they have a family history of the disease, to ensure they do not miss out on targeted treatment options.
What are the risks of undergoing genetic testing for MND?
The primary risks are psychological and ethical. A positive result can cause distress and reveal that biological relatives are also at risk of developing the disease, which can lead to complex family dynamics and anxiety.
The movement for expanded genetic testing represents a broader shift in neurology. By moving away from a one-size-fits-all diagnostic model, the medical community can better align patients with the specific therapies their biology requires. The success of this transition depends on the ability of healthcare systems to fund and implement widespread screening and the necessary support services to accompany it.
